COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)
ES34 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics
Search results
32 results
-
-
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
ES33 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics
-
COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)
This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).
-
COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)
ES27 . Key messages The content of this evidence review was up-to-date on 4 June 2020. See summaries of product characteristics
-
COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)
ES24 . Key messages The content of this evidence review was up-to-date
-
COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)
ES25 . Key messages The content of this evidence review was up-to-date on 20 April 2020. See summaries of product characteristics
-
COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis (ES26)
ES26 . Key messages The content of this evidence review was up-to-date on 13 May 2020. See summaries of product characteristics
-
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)
ES23 . Key messages The content of this evidence review was up-to-date
-
Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)
This document summarises the evidence base on suicide prevention: optimising medicines and reducing access to medicines as a means of suicide . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Shared decision making (KTT23)
This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .
-
Chemotherapy dose standardisation (KTT22)
This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Medicines optimisation in chronic pain (KTT21)
This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Safer insulin prescribing (KTT20)
This document summarises the evidence base on safer insulin prescribing . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)
This document summarises the evidence base on psychotropic medicines in people with learning disabilities whose behaviour challenges . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Multimorbidity and polypharmacy (KTT18)
This document summarises the evidence base on multimorbidity and polypharmacy . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)
This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)
This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants , including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Wound care products (KTT14)
This document summarises the evidence base on wound care products . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Antipsychotics in people living with dementia (KTT7)
This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Hypnotics (KTT6)
This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Asthma: medicines safety priorities (KTT5)
This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Lipid-modifying drugs (KTT3)
This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)
This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Antimicrobial stewardship: prescribing antibiotics (KTT9)
This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Biosimilar medicines (KTT15)
The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Non-steroidal anti-inflammatory drugs (KTT13)
The key therapeutic topic non-steroidal anti-inflammatory drugs has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Renin-angiotensin system drugs: dual therapy (KTT2)
The key therapeutic topic renin-angiotensin system drugs: dual therapy has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .
-
First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)
The key therapeutic topic first-choice antidepressant use in adults with depression or generalised anxiety disorder has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Minocycline (KTT11)
The key therapeutic topic minocycline has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Laxatives (KTT1)
The key therapeutic topic laxatives has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Three-day courses of antibiotics for uncomplicated urinary tract infection (KTT10)
The key therapeutic topic 3-day courses of antibiotics for uncomplicated urinary tract infection has been retired from the 2017 update of medicines optimisation: key therapeutic topics. Key points have been incorporated into the antimicrobial stewardship topic. See the key therapeutic topic antimicrobial stewardship: prescribing antibiotics for more information.
-
Omega-3 fatty acid supplements (KTT4)
The key therapeutic topic omega-3 fatty acid supplements has been incorporated into the key therapeutic topic lipid-modifying drugs. See lipid-modifying drugs for more information.